Skip to content

Effects of Sodium Bicarbonate Supplementation on Intermittent and Intense Task

Sodium Bicarbonate Supplementation Promotes Changes in Performance, Muscle Activity and Strength of Individuals Trained During the Performance of Intermittent and Intense Task? Randomized, Double-blind, Crossover Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03837886
Enrollment
12
Registered
2019-02-12
Start date
2019-10-20
Completion date
2019-11-30
Last updated
2019-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alkalosis, Metabolic, Electromyography, Fatigue, Sodium Bicarbonate

Brief summary

The aim of this study was to verify if sodium bicarbonate (NaHCO3) suplementation promotes changes in the performance, muscular activity and strength of individuals trained during the intermittent and intense task . Twelve trained adult men will participate in this randomized, double-blind, crossover clinical trial. Each participant should receive two types of intervention with a 14-day interval between conditions: alkalosis (ALK) in which gelatinous capsules containing 0.3 g.kg -1 of NaHCO 3 and placebo (PLA) are administered, in which 0.3 g.kg-1 of Calcium Carbonate (CaCO3). The following results will be considered: electromyographic activity (EMG) of the quadriceps muscle, peak torque, pH, lactate, and perception of effort, recovery and pain questionnaires, which will be collected during intermittent and high intensity DI protocol. ANOVA of repeated measures will be used to verify possible differences between groups.

Interventions

DIETARY_SUPPLEMENTSodium bicarbonate

The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.

DIETARY_SUPPLEMENTCalcium carbonate

The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate

Sponsors

Marcelo Martins Kalytczak
CollaboratorUNKNOWN
University of Nove de Julho
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
20 Years to 42 Years
Healthy volunteers
Yes

Inclusion criteria

* resistance trained men (minimum 12 moths resistance training experience)

Exclusion criteria

* diabetes mellitus; * respiratory (asthma, COPD), renal, metabolic, rheumatic and cardiovascular disorders; * acid-base balance disorder; * continuous use of some type of medication; * use of high-protein supplementation and creatine supplementation; * users of anabolic steroids.

Design outcomes

Primary

MeasureTime frameDescription
Electromyographic activity of the femoral quadriceps evaluated with electromyography equipment60 minutesThe electromyographic activity will be obtained during the execution of 10 series composed of ten repetitions of extension (concentric phase) and flexion (eccentric phase) of the knee joint, at an angular velocity of 120os-1 (radians per second), with interval of 1 minute interval between sets in an isokinetic dynamometer.
Peak torque assessed with isokinetic dynamometer equipment60 minutesThe peak torque will be obtained during the execution of 10 series composed of ten repetitions of extension (concentric phase) and flexion (eccentric phase) of the knee joint, at an angular velocity of 120os-1 (radians per second), with interval of 1 minute interval between sets.

Secondary

MeasureTime frameDescription
Lactate assessed with portable lactometer15 secondsThe lactate quantification will be performed before and after the test session characterized by the execution of 10 series composed of ten repetitions of extension (concentric phase) and flexion (eccentric phase) of the knee joint, at an angular velocity of 120os-1 (radians per second), with an interval of 1 minute between sets in an isokinetic dynamometer.

Countries

Brazil

Contacts

Primary ContactMarcelo M Kalytczak, PhD
marcelomkal@hotmail.com55 11 981595139

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026